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Malignant and non-malignant respiratory diseases account for >4.6 million deaths annually 
worldwide. Despite similar symptom burdens, serious inequities in access to palliative care 
persists for people with non-malignant respiratory diseases. 
 
Aim 
To compare functional decline and symptom distress in advanced malignant and non-
malignant lung diseases using consecutive, routinely collected, point-of-care national data. 
 
Setting/participants  
The Australian national Palliative Care Outcomes Collaboration collects functional status 
(Australia-modified Karnofsky Performance Status (AKPS)) and symptom distress (patient-
reported 0-10 numerical rating scale) in inpatient and community settings. Five years of data 
used Joinpoint and weighted scatterplot smoothing.  
 
Results  
In lung cancers (89,904 observations; 18,586 patients) and non-malignant end-stage 
respiratory diseases (14,827 observations; 4,279 patients), age at death was significantly 
lower in people with lung cancer (73 years; inter-quartile range (IQR) 65, 81) than non-
malignant end-stage respiratory diseases (81 years; IQR 73, 87 years; p<0.001). Four months 
before death, median AKPS was 40 in lung cancers and 30 in non-malignant end-stage 
respiratory diseases (p<0.001). Functional decline was similar in the two groups and 
accelerated in the last month of life. People with non-malignant diseases accessed palliative 
care later.  
 
Pain-related distress was greater with cancer and breathing-related distress with non-
malignant disease. Breathing-related distress increased towards death in malignant, but 
decreased in non-malignant disease. Distress from fatigue and poor sleep were similar for 
both.   
 
Conclusions 
In this large dataset unlike previous datasets, the pattern of functional decline was similar as 







What is the key question? 
Do the trajectories of functional decline and symptom intensity differ between people with 
late stage lung cancers and non-malignant end-stage respiratory diseases? 
 
What is the bottom line? 
Trajectories of functional decline are very similar between these two groups, but pain is the 
predominant symptom in people with cancer, while it is breathlessness in people with non-
malignant end-stage respiratory diseases.  
 
Why read on? 
In this large, consecutive cohort study, understanding these patterns of functional decline and 







Lung cancers and non-malignant end-stage respiratory diseases are significant causes of 
morbidity and mortality worldwide. Lung cancers cause 1.6 million deaths each year and is 
the most fatal cancer internationally. [1] Of the 200 million people with chronic obstructive 
pulmonary disease (COPD) globally, 65 million people are living with moderate to severe 
disease, generating more than three million deaths annually. [2,3] 
 
People with lung cancers and non-malignant end-stage respiratory diseases have been 
reported to experience a similar symptom burden, [4-8] but survival in lung cancer is 
generally shorter than people with end-stage lung diseases. [5,8] People with COPD are 
symptomatic for nearly six times as long as those with lung cancers [4] and have lower levels 
of function. [6,9,10] Despite similar palliative care needs experienced by those with these 
two conditions, [4,10,11] supportive and palliative care support for people with non-
malignant lung disease is less common than for cancer patients. Further, palliative care access 
for people with COPD appears to be driven largely by the presence of comorbid lung cancers. 
[12] Even in people with lung cancer, needs-based access to palliative care is often less than 
ideal.[13] If people with non-malignant end-stage respiratory diseases do access palliative 
care services, this often occurs much later than for people with lung cancer.[5,8,9,14-18]  
 
There are four functional patterns in the dying derived from activities of daily living (ADL) 
data: sudden death; terminal illness (decline in the last three months after a plateau period); 
organ failure (chronic remitting and relapsing diseases) and frailty.[19] Developments in 
disease-modifying therapies allow people to live longer with disease, potentially changing 
these proposed trajectories.[20] Although two contemporary patterns in trajectory of 
functional decline have been identified in the last 4 months of life in people who do not have 
lung cancers or non-malignant end-stage respiratory diseases,[20] there are few data, 
illustrating current patterns of disease trajectory dying from these conditions. Despite this, 
these less predictable trajectories have been suggested as a reason why people with non-
malignant disease have less access to palliative care. Studies of symptom burden by diagnosis 
show that populations with cancer have symptoms which often worsen rapidly over the 
weeks prior to death.[4,10,21,22] A small longitudinal study comparing people with lung 
cancer or COPD showed rapidly increasing symptoms due to lung cancer close to death, but 
that in people with COPD, symptoms gradually increased over a longer period of time.[4] 
Individual trajectories of breathlessness varied in people with both diagnoses,[4,10] although 
these patterns may not be representative of larger populations.    
 
The aim of this study was to describe and compare changes in function and symptom-related 
distress in people with lung cancers or non-malignant end-stage respiratory diseases, in a 
large national dataset of patient-reported, point-of-care clinical measures, in the last four 
months of life.   
 
Methods  
Study setting  
The Australian national Palliative Care Outcomes Collaboration (PCOC) is a voluntary 
program. Participating services represent more than 85% of all people referred for palliative 
care each year equating to patient outcome measures for about 25% of all predictable deaths 
in Australia annually. Currently, the data from PCOC represent 37.1% of all lung cancer 
deaths over that period and 6.7% of all deaths from respiratory diseases. Data were collected 
at point-of-care in inpatient and community settings at admission and discharge and at every 
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change in phase of care (‘stable’, ‘unstable’, ‘deteriorating’, and ‘terminal’).[23] Palliative 
care phase is a reliable measure that can be used to plan responsive clinical care.[24,25] 
PCOC patient/proxy reported outcomes data are used at the time that they are collected to aid 
clinical decision making and, when aggregated, routine benchmarking of outcomes between 
services. 
 
Study Design  
This was a repeated, cross-sectional consecutive cohort study using prospectively collected 
clinical data from the Australian national PCOC database with a similar methodology to 
previously described trajectories in other life-limiting illnesses.[20,25] Analysis and reporting 
of anonymised data collected as part of the PCOC programme were approved by the Human 
Research Ethics Committee of the University of Wollongong (approval ID: HE2006/045). 
Routine PCOC clinical data are de-identified and aggregated, and separate patient consent 
was not required. Using death as the anchor time point, data from the preceding four months 
were examined.  
 
Participants and variables  
This analysis included all patients with at least one recorded Australia-modified Karnofsky 
Performance Status (AKPS) score [26] who died in the care of participating palliative care 
services between 1st January 2013 – 31st December 2018. Data were integrated using a 
statistical linkage key in combination with the patient’s residential postcode. Diagnostic 
group was allocated based on the principal life-limiting illness that resulted in a palliative 
care referral. Patients were grouped into three diagnostic cohorts: lung cancers; chronic 
respiratory disease and all others (where the latter has been reported previously).[20]   
 
The Australia-modified Karnofsky Performance Status (AKPS) scale is an ordinal tool that 
reports functional status (100 –independent, no evidence of disease with ten point decrements 
to 0 – dead).[26] A person with an AKPS score of 40 is in bed more than 50% of the time.  
 
Symptom distress data were collected from patients at each clinical encounter and, if the 
patient was unable to respond, from their caregiver/proxy. The Symptom Assessment Scale is 
a numerical 0-10 patient self-rating scale (NRS) [8] used to capture symptom distress.  




Cohort characteristics were reported using descriptive statistics (counts and percentages). All 
longitudinal analyses of the trajectory of patient function were undertaken using number of 
days before death, which was the anchor point.[20] Joinpoint regression was used to identify 
time points prior to death associated with significant changes in the slope of functional 
decline at the group level in the lung cancers and non-malignant end-stage respiratory 
diseases cohorts over time. (Joinpoint Regression Program, Version 4.3.1.0 - April 2016; 
Statistical Methodology and Applications Branch, Surveillance Research Program, National 
Cancer Institute) Locally weighted scatterplot smoothing (lowess) was used to investigate 
trends in patient function (AKPS) and symptom distress. Lowess smoothing was undertaken 
using R 3.4.4 (R Core Team 2018, Vienna, Austria).  
 
Sensitivity analysis 
There are no agreed national or international criteria for referral to specialist palliative care. 
As such, late referrals have the potential to influence the modelled trajectories. To investigate 
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this, a sensitivity analysis was performed by re-running the regression model algorithm, with 
patients referred to palliative care during the last 14 days of life removed from the data set.  
 
Reporting quality framework 
The study is reported in accordance with the Strengthening The Reporting of Observational 
Studies in Epidemiology (STROBE) checklist.[27]  
 
Results  
A total of 89,904 observations were made from 18,586 patients with lung cancer and 14,827 
observations in 4,279 patients with non-malignant end-stage respiratory diseases. The 
majority of observations were made in the last ten days of life. (Figure 1) 
 
 
Figure 1.  Graph of mean Australia-modified Karnofsky Performance Scale (AKPS) 
trajectories in lung cancers (89,904 observations; 18,586 patients) and non-malignant 
end-stage respiratory diseases (14,827 observations; 4,279 patients) in the 120 days 
leading to death, including the incidence of observations in the study period. 
 
Demographic data (Table 1) show similar characteristics between the groups, with an 
exception of median age at death, being significantly lower in people with lung cancer (73 
years (inter-quartile range (IQR) 65, 81 years) than people with non-malignant end-stage 
respiratory diseases (81 years IQR 73, 87 years). Both groups contain fewer women than 
men, with the majority being born in Australia and almost all speaking English. Time from 
referral to death was longer in people with lung cancers (median of 22 days (IQR 6, 72 days) 





Table 1. Characteristics of the two diagnostic cohorts of thoracic life-limiting illnesses in 
prospectively collected national data from the participating palliative care services for 
the last 120 days of life.  






Patients  18,586 Patients  4,279  

















Female  7,379 39.7% 1,921 44.9% p<0.001 
  
Born in Australia 11,672 62.8% 2,730 63.8% p=0.173 
  
English speaking 16,839 90.6% 3.911 91.4% p=0.130 
  
Age at death 
p<0.001  median 73 81 
range (IQR) 0-103 (65-81) 0-103 (73-87) 
  
Australia-modified Karnofsky Performance Scale (AKPS) 
p<0.001  median 40 30 
range (IQR) 10-100 (20-50) 10-100 (30-50) 
  
Time from referral until death (days) 
p<0.001  median 22 6 
range (IQR) 0-2710 (6-72) 0-1852 (2-40) 
IQR – interquartile range 
 
Four months from the end of life, the median AKPS was 40 in people with lung cancer and 
30 in people with non-malignant end-stage respiratory diseases. (Figure 1). For changes in 
functional status over time, the scatterplot showing the mean daily AKPS and the fitted 
model superimposed are shown in Figure 2 and tabulated in Table 2. In the lung cancer 
cohort, the segmented regression algorithm found that a four break point model best 
described the trajectory of functional decline at the group level. At 120 days prior to death, 
the modelled average AKPS was 55.4. Function declined over the entire period, with 
significant changes occurring at 56, 20, 8 and 3 days prior to death. The most rapid decline in 
function occurs during the last three days of life, with a mean daily decrease in AKPS of 4.2 
points. The model for people with non-malignant end-stage respiratory diseases showed a 
similar model with three break points at 26, 8 and 2 days before death. (Table 2, Figure 2) 
 
Table 2 Summary of Joinpoint predicted AKPS from 120 days before death, at each 
break point and last recorded AKPS before death. 
 
 
Break point # Days until 
death 
Predicted AKPS Daily percentage 
change 
Lung cancers    
- 120 55.4 0.2% 
4 56 51.6 0.4% 
3 20 44.6 1.3% 
2 8 38.0 4.2% 
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1 3 29.7 14.8% 
- 0 16.4 - 
Non-malignant end-stage respiratory diseases   
- 120 49.6 0.2% 
3 26 40.9 0.7% 
2 8 35.0 5.4% 
1 2 23.9 17.2% 
- 0 15.7 - 
AKPS – Australia-modified Karnofsky Performance Status scale 
 
 
The sensitivity analysis removed data from people only referred in the last 14 days of life 
(Table 3). For both cohorts, removing referrals during the last 14-days of life had little impact 




Figure 2.  Matrix plot displaying the distribution of Australia-modified Karnofsky 
Performance Status scale (AKPS) from 16 weeks prior to death in the left hand panel, 
and mean daily AKPS and superimposed Joinpoint regression models in the 120 days 




Table 3 Results of Joinpoint regression models and sensitivity analyses for lung cancers 
and non-malignant end-stage respiratory diseases cohorts 
  




Full model   
   
Model Coefficients Estimate (95% confidence interval) 
Break point (days before death)a   
4 (further from death) 56 (45-68) - 
3 20 (16-25) 26 (12-44) 
2 8 (6-10) 8 (5-11) 
1 (closer to death) 3 (2-4) 2 (2-3) 
   
Rate of functional decline (slope)b Estimate (standard error) 
5 (further from death) 0.1 (0.008) - 
4 0.2 (0.011) 0.1 (0.010) 
3 0.6 (0.038) 0.3 (0.066) 
2 1.6 (0.121) 1.9 (0.211) 
1 (closer to death) 4.4 (0.115) 4.1 (0.408) 
   
Mean AKPS at death (Intercept)c 16.4 (0.134) 15.7 (0.293) 
   
   
Sensitivity analysisd  
   
Model Coefficients Estimate (95% confidence interval) 
Break point (days)a   
4 (further from death) 56 (46-67) - 
3 20 (17-23) 26 (13-40) 
2 8 (6-9) 7 (5-14) 
1 (closer to death) 3 (2-4) 2 (2-5) 
   
Rate of functional decline (slope)b Estimate (standard error) 
5 (further from death) 0.1 (0.007) - 
4  0.2 (0.010) 0.1 (0.010) 
3 0.6 (0.040) 0.3 (0.068) 
2 1.7 (0.154) 1.9 (0.457) 
1 (closer to death) 4.2 (0.151) 4.4 (0.792) 
  H 
Mean AKPS at death (Intercept)c 16.1 (0.175) 16.5 (0.602) 
   
AKPS – Australia-modified Karnofsky Performance Scale 
a The break points describe the number of days prior to death where there is a significant 
change in the rate of functional decline.  
b The model slope is rate of functional decline (i.e. the decrease in average AKPS for each 
day closer to death). Slope 1 indicates the rate of rate of functional decline in the period just 
prior to death. 
c The model intercept is the average AKPS on the day that the patient died.  
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d The sensitivity analysis describes the results obtained after re-running the algorithm with 
late referrals (last 14 days) removed from the analysis. 
 
For symptom distress, more people with lung cancer experienced distress from pain 
compared to people with non-malignant end-stage respiratory diseases over the whole 120 
days prior to death (Figure 3). Distress from breathing was greater in people with non-
malignant end-stage respiratory diseases for the entire study period, although distress reduced 
in the 20 days prior to death. (Figure 3) However, in people with lung cancer, distress from 
breathlessness worsened from about three weeks before death. Distress from fatigue and poor 
sleep were similar in both groups. (Figure 3)    
 
 
Figure 3.  Graphs of mean symptom distress (pain, breathlessness, fatigue & sleep) 
measured on a 0-10 numerical rating scale plotted against the 120 days before death in 
prospectively collected national data in people with lung cancers (89,904 observations; 
18,586 patients) and non-malignant end-stage respiratory diseases (14,827 observations; 




In this mortality follow-back analysis of a large prospectively collected data set, the pattern 
of functional decline in the last 120 days of life occurred in parallel, unlike previous 
descriptions. Although overall symptom burden was similar, the pattern differed between the 
two disease groups; pain was mainly a feature of lung cancer, and breathlessness of non-
malignant lung disease. Despite this, people with non-malignant disease accessed palliative 
care later. Breathlessness increased nearer death in people with malignant disease, and 
decreased in people with non-malignant, lung diseases.   
 
These data potentially challenge some previous models based on smaller data sources with 
derived measures,[19] from qualitative interviews and expert opinion showing different 
patterns of functional decline. However, other findings were consistent with previous reports. 
Functional decline accelerated for both groups closer to death confirming other studies that 
excluded people with thoracic diseases,[20] including other mortality follow-back 
studies.[28] People with non-malignant end-stage respiratory diseases had a lower baseline 
functional status,[9-11,19] perhaps due to previously noted older age at the end of life.[4,5,8] 
However, the difference in functional status between the group was less marked in our study; 
clinically marginal at most. Despite the similarities in trajectories, people with non-malignant 
disease were referred to palliative care later than people with lung cancer, consistent with 
other population studies. [5,8,9,14-18]  
  
Like others, we found a similar overall symptom burden is experienced by people with lung 
cancers and non-malignant end-stage respiratory diseases, but lung cancer is associated with 
worse pain-related distress [5,7,29] and non-malignant end-stage respiratory diseases 
experience clinically important greater distress from breathlessness.[4,22,30] People with 
lung cancer experienced greater breathlessness-related distress as death approaches,[11,31] 
and those with non-malignant disease experienced increasing pain-related distress prior to 
death.  
 
Prevalence of sleeping difficulties has been reported at 35% [31] comparable to the baseline 
values in this study. However, we found no difference by disease group unlike a previous 
review [8] where those with lung cancer were three times more likely to experience insomnia 
(30% vs 10%). Findings related to fatigue were consistent with previous reports.[8,31,32]   
 
Strengths and Limitations  
The Australian national Palliative Care Outcomes Collaboration (PCOC) collects data 
predominantly from services providing specialist palliative care, which may overstate 
population prevalence of symptoms as only a proportion of people with life-limiting illness 
access specialist services. Potentially, the people with greater symptom burden may be more 
likely to be referred to palliative care services.  
 
There are no universal criteria for referral to specialist palliative care and only about half of 
people dying are referred.[15,16] Therefore, these trajectories may not be representative of all 
people dying with lung cancers or people with non-malignant end-stage respiratory diseases. 
PCOC data are collected when patients interact with healthcare services. Therefore, one also 
needs to consider the impact of other factors on referral and uptake of specialist palliative 





This is the largest trajectory study undertaken [20,22,33] with two distinct cohorts with 
thoracic diseases: lung cancers or non-malignant end-stage respiratory diseases. This is a 
consecutive case-series, which lessens selection bias. Standardised assessment tools including 
AKPS were used for both diagnostic groups collected at point-of-care allowing comparisons 
between the disease trajectories.[26]  Many studies look at non-small cell lung cancer 
(NSCLC) and COPD, rather than all lung cancers and all non-malignant end-stage respiratory 
diseases. Therefore, any differences between previous studies and these results may be 
explained by the current study including more diagnoses.  
 
Measures of multi-morbidity were not available in this study, although a simultaneous 
diagnosis of non-malignant end-stage respiratory diseases and lung cancers is possible, 
especially given shared risk factors. Studies have shown 14.5-43.0% of people with lung 
cancer are reported to also have COPD.[11,34] However, including people with both non-
malignant end-stage respiratory diseases and lung cancers simultaneously represents a more 
genuine clinical picture as these patients with comorbidity are seen in practice although 
people with lung cancer are much more likely to be referred to palliative care.[12] 
 
A key challenge in assessing trajectories of functional decline is that measures such as AKPS 
is an ordinal variable. To analyse with tools such as Joinpoint requires the assumption that 
the scales are close to a continuous variable where each step on the scale is close to equal to 
all other steps. There is no simple way to establish this property but, importantly, in this study 
the two groups had data collected contemporaneously by the same clinicians, and the 
analyses were identical for both groups in order to allow a direct comparison.   
 
Our study analysed aggregate data which we recognise as poorly representative of individual 
trajectories of those dying with non-malignant disease; previously reported as variable and 
even “chaotic”.[35] It is interesting to note, however, that in studies of individual trajectories 
only a minority of those studies followed the previously described theoretical trajectories of 
dying. 
 
Implications for Clinical Practice  
Use of palliative care services improves quality of life in people with lung cancer [36] and, 
with early access, is associated with patient outcomes and reduced costs of end-of-life 
care.[11] This, alongside the comparable symptom burden, similar functional decline and 
significant global burden of chronic respiratory diseases, highlights the need for more 
proactive and patient-centred policies regarding active referral to palliative care for people 
with non-malignant end-stage respiratory diseases. A focus on current needs and concerns 
would mitigate against the challenges of prognostication in both malignant and non-
malignant disease.  
 
Given these findings, distress from breathing should be specifically identified and assessed. 
Given similar trajectories of functional decline, ensuring adequate pre-planning for 
deteriorating physical function and increasing needs for assistance with activities of daily 
living is essential. Occupational therapists and physiotherapists in particular employ a range 
of strategies that aim to optimise patient function through the non-pharmacological 
management of breathlessness.[37] The ability to remain as active as possible for as long as 
possible is a priority for those with non-malignant end-stage respiratory diseases.[38] 
Defining needs generated by functional decline is the responsibility of every health 
professional who has contact with people who have end-stage disease so that appropriate 
13 
 
allied health practitioners can be engaged to help optimise function before functional decline 
accelerates.[39]  
 
Implications for future research 
This study combined all non-malignant end-stage respiratory diseases. It is possible that there 
are different trajectories and symptom burden profiles for differing causes of malignant (non-
small cell lung cancer, small cell lung cancer) and non-malignant end-stage respiratory 
diseases. Future research will need to have data on sufficient numbers of patients for each 
respiratory condition that leads to end-stage disease in order to define any differences 
between causes of non-malignant end-stage respiratory diseases.  
 
This study provides robust evidence for what had previously been assumed as the case in 
functional decline and symptom distress at the end-of-life. The data on sleep need further 
prospective investigation, especially distinguishing between those who do and do not have 
long term sleep problems such as obstructive sleep apnoea.  
 
Generalisability   
The PCOC data are collected from a high-income country with universal health insurance and 
well-established specialist palliative care services, and therefore findings can only be 
compared to similar countries. Further, PCOC data will not be captured for people who have 
not been referred to a participating service. 
 
Conclusions  
This large mortality follow-back study showed a similar pattern of functional decline in 
people dying of lung cancers or non-malignant lung diseases. Overall, both groups had an 
equivalent symptom burden but referral for palliative care services was later for those with 
non-malignant disease. Timely access to palliative care for both groups should be both 
possible and actioned. These data speak strongly to the need for proactive, need-based 
identification immediately as the final, inexorable decline commences so that the appropriate 
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